- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer
April 4th 2024, 1:00pm
Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
March 27th 2024, 8:00pm
ESMO Targeted Anticancer Therapies Congress
MK-1084 had an acceptable toxicity profile when administered as a monotherapy in patients with KRAS G12C–mutated previously treated solid malignancies.
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
March 25th 2024, 8:11pm
Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
March 25th 2024, 7:00pm
Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab
March 22nd 2024, 9:09pm
Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.
Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast Cancer
March 22nd 2024, 8:52pm
Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.
Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial Cancer
March 21st 2024, 10:34pm
Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.
Dr Tanyi on the Use of Pafolacianine for Intraoperative Molecular Imaging in FRα+ Ovarian Cancer
March 21st 2024, 10:26pm
Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.
Avutometinib Plus Defactinib Shows High Response Rates in Heavily Treated LGSOC
March 21st 2024, 10:06pm
Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.
Becotarug Plus Osimertinib Elicits Responses in EGFR Exon 20 Insertion+ NSCLC
March 21st 2024, 2:31pm
Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.
Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC
March 20th 2024, 9:24pm
Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.
2024 ACRO Summit Underscores the Importance of Continued Education in Radiation
March 20th 2024, 9:02pm
Steven E. Finkelstein, MD, DABR, FACRO, discusses the importance of disseminating treatment advancements and ongoing research in radiation oncology.
Exploratory Analysis Shows Perioperative Nivolumab Confers Benefit in Resectable NSCLC, Irrespective of Neoadjuvant Treatment Cycles
March 20th 2024, 8:00pm
Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.
Preclinical Data Suggest XPO1 Offers Potential Treatment Pathway in TP53 Wild-Type LGSOC and CCOC
March 20th 2024, 6:05pm
Treatment with XPO1 inhibitors could be effective and warrants further investigation in low-grade serous and clear cell ovarian cancer.
ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer
March 20th 2024, 5:41pm
ctDNA may aid clinicians in determining whether to proceed with or discontinue PARP inhibitor maintenance therapy for patients with recurrent epithelial ovarian cancer.
NT219 Plus Cetuximab Demonstrates Efficacy, Tolerability in SCCHN
March 20th 2024, 2:00pm
ESMO Targeted Anticancer Therapies Congress
NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Dr Mahtani on Unique Challenges Women in Oncology Experience During Career Transitions
March 19th 2024, 8:33pm
PER® Miami Breast Cancer Conference
Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.
Ixabepilone Plus Bevacizumab Generates Survival Benefit and Responses in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024, 7:40pm
Ixabepilone plus bevacizumab produced a survival advantage and high response rates vs ixabepilone alone in platinum-resistant ovarian cancer.
NXP800 Under Further Investigation in Platinum-Resistant, ARID1A-Mutated Ovarian Cancer
March 19th 2024, 7:12pm
A phase 1b trial is investigating the novel GCN2 kinase activator NXP800 in patients with platinum-resistant, ARID1A-mutated ovarian cancer.
CRX100 Elicits Activity, Is Well Tolerated in Recurrent, Platinum-Resistant Ovarian Cancer
March 19th 2024, 6:32pm
CRX100 plus a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in patients with recurrent, platinum-resistant ovarian cancer.